Actively Recruiting

Phase 4
Age: 18Years - 80Years
MALE
ID05629494

Effect of Non-steroidal Anti-inflammatory Drugs on Serum Prostate Specific Antigen Level

Led by Albany Medical College · Updated on 2024-10-18

198

Participants Needed

3

Research Sites

39 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Prostate cancer is the most commonly diagnosed cancer in men in the United States. Many men undergo prostate biopsy due to elevated prostate-specific antigen (PSA) levels, but often no cancer is found. Elevated PSA levels can result from inflammation, benign prostate enlargement, infections, or natural variations. This research aims to study whether over-the-counter anti-inflammatory drugs like ibuprofen or naproxen can lower PSA levels and potentially reduce unnecessary biopsies. Participants are randomly assigned to one of two groups. One group will have a repeat PSA test after about 6 weeks without treatment, while the other group will take ibuprofen 400 mg three times daily for 10 days before repeating the PSA test at around 6 weeks. The study compares changes in PSA levels between these groups to understand the effect of anti-inflammatory medications. During the study, participants will have PSA tests, and their symptoms will be monitored using questionnaires like the International Prostate Symptom Score over 3 to 12 months. Researchers will track kidney function to identify any risks from ibuprofen use and assess how long any changes in PSA levels last up to 1.5 years. The goal is to identify safer ways to manage elevated PSA levels and avoid unnecessary procedures. Total participation may extend up to a year or more for follow-up assessments.

CONDITIONS

Brief Title

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

Who Can Participate

Age: 18Years - 80Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male patients between 18 and 80 years old with a screening PSA greater than 3 ng/ml considered for further testing
  • Normal digital rectal examination within the past two years, documented by a healthcare provider
  • No symptoms suggesting an acute urinary tract infection such as painful or unusual urination
Not Eligible

You will not qualify if you...

  • Allergy or hypersensitivity to ibuprofen or other NSAIDs
  • History of peptic ulcers, gastrointestinal bleeding, or NSAID-related gastrointestinal problems
  • Known bleeding disorders
  • Severe chronic kidney disease with eGFR less than 30 mL/min/1.73 m2
  • Heart failure or significant heart disease
  • Poorly controlled high blood pressure
  • Active urinary tract infections or bacteria in urine
  • Use of 5-alpha reductase inhibitors unless on stable dose for at least 6 months
  • Known prostate cancer or recent prostate MRI or biopsy within one year
  • Urinary tract procedures like catheter or cystoscopy in past 6 weeks
  • Use of anti-inflammatory or steroid drugs concurrently
  • Use of dual-antiplatelet or anticoagulant therapy except low-dose aspirin
  • Severe liver disease shown by abnormal liver tests
  • Any other medical condition that contraindicates NSAID use

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 10 days

Participants receive Ibuprofen 400 mg three times per day for 10 days.

1 treatment period of 10 days

Treatment

Duration - 6 weeks (± 1 week)

Participants who do not receive treatment will have their PSA level repeated after 6 weeks.

1 follow-up visit for PSA test

Trial Site Locations

Total: 3 locations

1

University of Chicago Medical Center

Chicago, Illinois, United States, 60637

Actively Recruiting

2

Albany Medical Center

Albany, New York, United States, 12208

Actively Recruiting

3

Penn State-Hershey Medical Center

Hershey, Pennsylvania, United States, 17033

Actively Recruiting

Loading map...

Research Team

B

Brenda Romeo

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With...

Prostate Cancer

Actively Recruiting

1 location

A Phase 1b Study of 177Lu-PSMA-617 Combined With Liver Direc...

Metastatic Prostate Cancer

Actively Recruiting

1 location

18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Phase III Ac...

Prostate Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here